職務(wù)：研究員/碩士生導(dǎo)師/所長

學(xué)歷：博士

電子郵件： bixingzhao@gmail.com

主要研究方向：腫瘤相關(guān)細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)通路、免疫治療與精準(zhǔn)醫(yī)學(xué)方面的基礎(chǔ)與臨床轉(zhuǎn)化研究

教育工作經(jīng)歷：

1999/09 - 2003/07，廈門大學(xué)，生物科學(xué)， 本科

2003/09 - 2006/07，廈門大學(xué)，細(xì)胞生物學(xué)，碩士

2006/09 - 2011/04，廈門大學(xué)，細(xì)胞生物學(xué)，博士

2011/04 - 2014/12，廈門大學(xué)附屬中山醫(yī)院，博士后

2014/08 - 2014/11，美國德克薩斯州立大學(xué)圣安東尼奧健康科學(xué)中心，訪問學(xué)者

2015/01 - 至今，福建醫(yī)科大學(xué)孟超肝膽醫(yī)院，副研究員，研究員

2017/09 – 2022/12，福建醫(yī)科大學(xué)孟超肝膽醫(yī)院肝病研究所，副所長

2017/06 - 至今，beat365在線體育官網(wǎng)孟超醫(yī)學(xué)與交叉科學(xué)中心，副教授、碩士生導(dǎo)師

2022/12 – 至今，福建醫(yī)科大學(xué)孟超肝膽醫(yī)院肝病研究所，所長

教學(xué)簡介：

參與承擔(dān)本科生課程《腫瘤生物學(xué)》教學(xué)。

科研簡介：主要從事腫瘤相關(guān)細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)通路、免疫治療與精準(zhǔn)醫(yī)學(xué)方面的基礎(chǔ)與臨床轉(zhuǎn)化研究。主持國家自然科學(xué)基金面上項(xiàng)目、科技部重點(diǎn)專項(xiàng)等多項(xiàng)國家級(jí)和省市級(jí)研究課題。在The EMBO Journal, Signal Transduction and Targeted Therapy, Theranostics等國際知名期刊上發(fā)表SCI收錄論文四十多篇。入選福建省第二批“雛鷹計(jì)劃”青年拔尖人才，福建省百千萬人才工程省級(jí)人選，福建省高層次人才（C類）；曾獲得福建省科技進(jìn)步一等獎(jiǎng)、福建省自然科學(xué)一等獎(jiǎng)、廈門市科學(xué)技術(shù)進(jìn)步一等獎(jiǎng)、福州市青年科技獎(jiǎng)、福建醫(yī)學(xué)科技獎(jiǎng)、福建省抗癌協(xié)會(huì)科技進(jìn)步一等獎(jiǎng)等榮譽(yù)。

社會(huì)兼職：福建省醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)青年委員會(huì)副主任委員、中國抗癌協(xié)會(huì)抗癌藥物專業(yè)委員會(huì)委員、中國醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合醫(yī)師分會(huì)基礎(chǔ)與轉(zhuǎn)化醫(yī)學(xué)專業(yè)委員會(huì)委員、中國醫(yī)藥生物技術(shù)協(xié)會(huì)科研實(shí)驗(yàn)室建設(shè)與管理分會(huì)委員、福建省藥理學(xué)會(huì)腫瘤藥理專業(yè)委員會(huì)常委、中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)肝病基礎(chǔ)醫(yī)學(xué)與實(shí)驗(yàn)診斷協(xié)作組成員、福建省醫(yī)學(xué)會(huì)外科學(xué)分會(huì)實(shí)驗(yàn)外科及轉(zhuǎn)化醫(yī)學(xué)學(xué)組委員。

科研項(xiàng)目：

1. 福建省科技創(chuàng)新聯(lián)合資金項(xiàng)目（2021Y9032），環(huán)狀RNA腫瘤新抗原疫苗在腫瘤免疫治療中的應(yīng)用研究，2022/10-2025/10，100萬，主持。

2. 福建省中央引導(dǎo)地方科技發(fā)展資金項(xiàng)目（2022L3030），肝癌免疫逃逸相關(guān)lncRNA調(diào)控網(wǎng)絡(luò)研究(福建省肝膽胰腫瘤臨床醫(yī)學(xué)研究中心)，2022/08-2025/08，40萬，主持。

3. 福建省衛(wèi)生教育聯(lián)合攻關(guān)計(jì)劃項(xiàng)目（2019-WJ-19），長鏈非編碼RNA FAM99A在缺氧誘導(dǎo)的肝癌轉(zhuǎn)移中的作用及機(jī)制研究，2019/09-2022/09，20萬，主持。

4. 福建省衛(wèi)生健康中青年骨干人才培養(yǎng)項(xiàng)目（2020GGA072），METTL16通過調(diào)控LncRNA AC079360.1 m6A甲基化促進(jìn)肝癌侵襲轉(zhuǎn)移，2021/01-2023/12，10萬，主持。

5. 福州市衛(wèi)生健康系統(tǒng)科技計(jì)劃創(chuàng)新團(tuán)隊(duì)培育項(xiàng)目（2021-S-wt2），長鏈非編碼RNA Lnc-PLA2G4A-4通過miR-23b/Versican信號(hào)軸調(diào)控肝癌的侵襲轉(zhuǎn)移，2021/09-2024/09，8萬，主持。

6. 國家自然科學(xué)基金面上項(xiàng)目（81672376），SALL4及其相互作用蛋白對(duì)肝癌治療抗性的調(diào)控功能研究，2017/01-2020/12，57萬，主持。

7. 國家重點(diǎn)研發(fā)計(jì)劃“科技助力經(jīng)濟(jì)2020”重點(diǎn)專項(xiàng)（SQ2020YFF0426513），病毒性肝炎相關(guān)肝癌人群預(yù)警和早篩試劑研發(fā)，2020/07-2022/6，100萬，合作主持。

8. 福州市衛(wèi)生計(jì)生系統(tǒng)科技計(jì)劃創(chuàng)新團(tuán)隊(duì)培育項(xiàng)目(2017-S-wt2)，Ku80通過SALL4調(diào)控肝癌細(xì)胞干性，2017/08-2020/07，8萬，主持。

9. 福建省醫(yī)學(xué)創(chuàng)新課題（2016-CX-48） SALL4在肝癌細(xì)胞DNA損傷修復(fù)中的作用研究，2016/10-2019/09，12萬，主持。

10. 福建省自然科學(xué)基金面上項(xiàng)目（2016J01417），10-23 型脫氧核酶靶向SALL4 抑制肝癌細(xì)胞侵襲轉(zhuǎn)移的實(shí)驗(yàn)研究，2016/04-2019/04，5萬，主持。

11. 福州市科技計(jì)劃項(xiàng)目（2015-S-143-19），靶向SALL4基因的microRNA對(duì)人肝癌細(xì)胞惡性表型的影響，2015/04-2018/03，3萬，主持。

12. 國家自然科學(xué)基金青年項(xiàng)目（81302069），Cx32通過p53信號(hào)通路調(diào)控肝癌細(xì)胞侵襲轉(zhuǎn)移，2014/01-2016/12，24萬，主持。

13. 中國博士后科學(xué)基金面上項(xiàng)目（2013M531550），CX32通過p53和Akt信號(hào)通路調(diào)控肝癌細(xì)胞增殖與侵襲轉(zhuǎn)移，2013/01-2015/01，5萬，主持。

14. 福建省自然科學(xué)基金青年創(chuàng)新項(xiàng)目（2012D055），細(xì)胞連接蛋白connexin32在肝癌發(fā)生發(fā)展中的作用研究，2012/07-2013/11，4萬，主持。

已發(fā)表論文：（*為通訊作者）

(1) Lin Y, Wang F, Zhong Y, Cheng NM, Xiong J, Zheng X, Zhou Y, Gao S, Li F, Wang Y, Yang X, Zhao B*. Long non-coding RNA COX7C-5 promotes hepatocellular carcinoma progression via miR-581/ZEB2 axis. Cellular Signalling. 2023; 101: 110501.

(2) You S, Luo Z, Cheng N, Wu M, Lai Y, Wang F, Zheng X, Wang Y, Liu X, Liu J, Zhao B*. Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression. Drug Delivery and Translational Research. 2023;13:782-794

(3) Bixing Zhao#, Kun Ke#, Yingchao Wang#, Fei Wang#, Yingjun Shi, Xiaoyuan Zheng, Xiaoyu Yang, Xiaolong Liu*, Jingfeng Liu*, HIF-1α and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC metastasis. Signal Transduction and Targeted Therapy. 2020; 5:118

(4) Liu J, Wang F, Zhang Y, Liu J, Zhao B*. ADAR1-Mediated RNA Editing and Its Role in Cancer. Front Cell Dev Biol. 2022;10:956649

(5) Ying Sun#, Xiaoyuan Zheng#, Hui Yuan, Geng Chen, Jiahe Ouyang, Jingfeng Liu, Xiaolong Liu, Xiaohua Xing*, Bixing Zhao*, Proteomic Analyses Reveal Divergent Ubiquitylation Patterns in Hepatocellula Carcinoma Cell Lines With Different Metastasis Potential. Journal of proteomics. 2020;225:103834.

(6) Bixing Zhao#, Yingchao Wang#, Xionghong Tan, Kun Ke, Cuilin Zhang, Yunzhen Gao, Naishun Liao, Yuan Dang, Yingjun Shi, Youshi Zheng, Xiaolong Liu*, Jingfeng Liu*, An optogenetic controllable T cell system for hepatocellular carcinoma immunotherapy. Theranostics. 2019; 9(7): 1837-1850.

(7) Bixing Zhao; Yingchao Wang; Xionghong Tan; Kun Ke; Xiaoyuan Zheng; Fei Wang; Shubing Lan; Naishun Liao; Zhixiong Cai; Yingjun Shi; Youshi Zheng; Yongping Lai; Lili Wang; Qin Li; Jingfeng Liu; Aimin Huang*; Xiaolong Liu*; Inflammatory Micro-environment Contributes to Stemness Properties and Metastatic Potential of HCC via the NF-kappaB/miR-497/SALL4 Axis. Molecular therapy oncolytics. 2019; 15, 79-90

(8) Bixing Zhao#, Xiaoyuan Zheng#, Xionghong Tan, Kun Ke, Fei Wang, YingchaoWang, Xiaohua Xing, Cuilin Zhang, Ping Hu, Shubing Lan, Qin Li, Aimin Huang*,  Xiaolong Liu*. Ku80 negatively regulates the expression of OCT4 via competitive binding to SALL4 and promoting lysosomal degradation of OCT4. The International Journal of Biochemistry & Cell Biology. 2020,118: 105664.

(9) Xing X, Yuan H, Sun Y, Ke K, Dong X, Chen H, Liu X, Zhao B*, Huang A*. ANXA2Tyr23 and FLNASer2152 phosphorylation associate with poor prognosis in hepatic carcinoma revealed by quantitative phosphoproteomics analysis. Journal of proteomics. 2019, 200:111-122.

(10) Hongzhi Liu#, Hui Chen#, Xiaomo Wu, Ying Sun, Yingchao Wang, Yongyi Zeng , Geng Chen, Xiaolong Liu, Xiaohua Xing*, Bixing Zhao*, Jingfeng Liu, The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Management and Research. 2019;11: 2935-2946

(11) Shubing Lan, Xiaoyuan Zheng, Ping Hu, Xiaohua Xing, Kun Ke, Fei Wang, Niangmei Cheng, Qiuyu Zhuang, Xiaolong Liu, Jingfeng Liu, Bixing Zhao*, Yingchao Wang*. Moesin facilitates metastasis of Hepatocellular carcinoma cells by improving invadopodia formation and activating β-catenin/MMP9 axis. Biochemical and Biophysical Research Communications. 2020; 524(4):861-868.

(12) Youshi Zheng#, Naishun Liao#, Yuan Wu, Ju Gao, Zhenli Li, Wenwen Liu, Yingchao Wang, Ming Li, Xiaolou Li, Li Chen, Wenmin Zhang*, Bixing Zhao*, High expression of B7H2 or B7H3 is associated with poor prognosis in hepatocellular carcinoma, Molecular Medicine Reports. 2019; 19: 4315-4325.

(13) B. Zhao, W. Zhao, Y. Wang, Y. Xu, J. Xu, K. Tang, S. Zhang, Z. Yin, Q. Wu, and X. Wang*, Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways. Oncotarget, 2015. 6(12): p. 10116-33.

(14) B. Zhao, H. Chen, X. Du, J. Luo, J. He, R. Wang, Y. Wang, R. Wu, R. Hou, M. Hong, and Q. Wu*, Orphan receptor TR3 enhances p53 transactivation and represses DNA double-strand break repair in hepatoma cells under ionizing radiation. Molecular Endocrinology, 2011. 25(8): 1337-50.

(15) B. Zhao, H. Chen, N. Lei, G. Li, W. Zhao, Y. Zhan, B. Liu, S. Lin, and Q. Wu*, p53 mediates the negative regulation of MDM2 by orphan receptor TR3. The EMBO journal, 2006. 25(24): 5703-15.

(16) X.Lin^#, B. Zhao^#, H. Chen, X. Ye, C. Yang, H. Zhou, M. Zhang, S. Lin, and Q. Wu, RXRalpha acts as a carrier for TR3 nuclear export in a 9-cis retinoic acid-dependent manner in gastric cancer cells. J Cell Sci, 2004. 117(Pt 23):5609-21.

(17) 邢曉華，袁暉，趙必星*. NEDD8抑制劑MLN4924抑制肝細(xì)胞癌惡性表型的研究.山西醫(yī)科大學(xué)學(xué)報(bào),2021,52:123-128.

(18) 王珊,王菲,鄭曉源,趙必星*. 靶向SALL4脫氧核酶抑制肝細(xì)胞癌惡性表型的實(shí)驗(yàn)研究.山西醫(yī)科大學(xué)學(xué)報(bào),2019(11):1499-1504.

(19) 賴永平,曾金華,譚雄紅,柯坤,趙必星*,成簇規(guī)律間隔的短回文重復(fù)序列及其相關(guān)蛋白9敲除Ku80基因提高HEK293T細(xì)胞對(duì)阿霉素的敏感性, 中華實(shí)驗(yàn)外科雜志, 2018, 35(8): 1437-1440.

(20) Liao N, Su L, Zheng Y, Zhao B, Wu M, Zhang D, Yang H, Liu X, Song J. In Vivo Tracking of Cell Viability for Adoptive Natural Killer Cell-Based Immunotherapy by Ratiometric NIR-II Fluorescence Imaging. Angew Chem Int Ed Engl. 2021;60(38):20888-20896.

(21) Liu H, Lin S, Ao X, Gong X, Liu C, Xu D, Huang Y, Liu Z, Zhao B, Liu X, Han X, Ye H. Meta-analysis of transcriptome datasets: An alternative method to study IL-6 regulation in coronavirus disease 2019. Comput Struct Biotechnol J. 2021;19:767-776.

(22) Xing X, Yuan H, Liu H, Tan X, Zhao B, Wang Y, Ouyang J, Lin M, Liu X, Huang A. Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma. Genomics Proteomics Bioinformatics. 2021;19(1):94-107.

(23) Zhong Y, Yang Y, He L, Zhou Y, Cheng N, Chen G, Zhao B, Wang Y, Wang G, Liu X. Development of Prognostic Evaluation Model to Predict the Overall Survival and Early Recurrence of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:301-312.

(24) Qiao S, Xin F, Wu M, Zheng Y, Zhao B, Zhang C, Liu X, Wei Z, Liu J. A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy. J Mater Chem B. 2021;9(25):5083-5091.

(25) Xiaohua Xing, Hui Yuan, Ying Sun, Kun Ke, Xiuqing Dong, Hui Chen, Xiaolong Liu, Bixing Zhao, Aimin Huang. Dataset for quantitative phospho-proteomics analysis of a serial hepatoma cell lines with increasing invasion and metastasis potential. Data in Brief, 2019; 27:104634.

(26) Naishun Liao, Yingjun Shi, Yingchao Wang, Fangyu Liao, Bixing Zhao, Youshi Zheng, Yongyi Zeng, Xiaolong Liu, Jingfeng Liu. Antioxidant preconditioning improves therapeutic outcomes of adipose tissue-derived mesenchymal stem cells through enhancing intrahepatic engraftment efficiency in a mouse liver fibrosis model. Stem Cell Res Ther. 2020;11(1):237.

(27) Lin X, Huang Y, Sun Y, Tan X, Ouyang J, Zhao B, Wang Y, Xing X, Liu J. 4E-BP1Thr46 Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC. Cancer Management and Research, 2020, 12: 103-115.

(28) Liuping Luo, Lihong Chen, Kun Ke, Bixing Zhao, Lili Wang, Cuilin Zhang, Fei Wang, Naishun Liao, Xiaoyuan Zheng, Xiaolong Liu, Yingchao Wang, Jingfeng Liu, High Expression Levels of CLEC4M Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. Oncol Lett. 2020;19(3):1711-1720.

(29) Y Wang#, G Wang#, X Tan#, K Ke, B Zhao, N Cheng, Y Dang, N Liao, F Wang, X Zheng, Q Li, X Liu*, J Liu*. MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. Oncogenesis, 2019, 8(12):67.

(30) Liao, N., Shi, Y., Zhang, C., Zheng, Y., Wang, Y., Zhao, B., Zeng, Y., Liu, X., and Liu, J. Antioxidants inhibit cell senescence and preserve stemness of adipose tissue-derived stem cells by reducing ROS generation during long-term in vitro expansion. Stem cell research & therapy. 2019; 10:306

(31) Zhang Xiang; Wang Fei; Huang Yanbing; Ke Kun; Zhao Bixing; Chen Lihong; Liao Naishun; Wang Lei; Li Qin; Liu Xiaolong; Wang Yingchao & Liu Jingfeng. FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition. Cancer Management and Research. 2019;11:1653-1665

(32) Liu Z, Wu S, Wang L, Kang S, Zhao B, He F, Liu X, Zeng Y, Liu J. Prognostic Value of MicroRNA-497 in Various Cancers: A Systematic Review and Meta-Analysis. Dis Markers. 2019, 2019: 2491291.

(33) Ke K, Chen G, Cai Z, Huang Y, Zhao B, Wang Y, Liao N, Liu X, Li Z, Liu J. Evaluation and prediction of hepatocellular carcinoma prognosis based on molecular classification. Cancer management and research, 2018, 10: 5291-5302.

(34) Yan, S., Cui, S., Ke, K., Zhao, B., Liu, X., Yue, S., & Wang, P. Hyperspectral stimulated Raman scattering microscopy unravels aberrant accumulation of saturated fat in human liver cancer. Analytical chemistry. 2018; 90: 6362?6366

(35) Wu, M., Lin, X., Tan, X., Li, J., Wei, Z., Zhang, D., Zheng, Y., Zheng, A., Zhao, B., ... & Liu, X. Photo-responsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp shRNA and Doxorubicin to Optimize and Enhance Synergistic Therapy of Multidrug-resistant Cancer. ACS applied materials & interfaces. 2018, 10(23): 19416-19427.

(36) Wu, M., Li, J., Lin, X., Wei, Z., Zhang, D., Zhao, B., ... & Liu, J. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery. Biomaterials science. 2018, 6(6): 1457-1468.

(37) Liao, N., Zheng, Y., Xie, H., Zhao, B., Zeng, Y., Liu, X., & Liu, J. Adipose tissue-derived stem cells ameliorate hyperglycemia, insulin resistance and liver fibrosis in the type 2 diabetic rats. Stem cell research & therapy. 2017,8(1): 286.

(38) Wei, Z., Lin, X., Wu, M., Zhao, B., Lin, R., Zhang, D. Zhang, Y., Liu, G., Liu, X. & Liu, J. Core-shell NaGdF 4@ CaCO 3 nanoparticles for enhanced magnetic resonance/ultrasonic dual-modal imaging via tumor acidic micro-enviroment triggering. Scientific Reports, 2017, 7(1): 5370.

(39)W. Chen, L. Chen, Z. Cai, D. Liang, B. Zhao, Y. Zeng, X. Liu, and J. Liu, Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma. Tumour Biol, 2016, 37(7):9343-55

(40) W. Zhao, Y. Xu, J. Xu, D. Wu, B. Zhao, Z Yin, and X. Wang. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. Int Immunopharmacol. 2015. 26(2): 314-21.

(41) W. Zhao, L. Zhang, Y. Xu, Z. Zhang, G. Ren, K. Tang, P. Kuang, B. Zhao, Z. Yin, and X. Wang, Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest, 2014. 94(2): 182-91.

(42) W. Wang, Y. Wang, H. Chen, Y. Xing, F. Li, Q. Zhang, B. Zhou, H. Zhang, J. Zhang, X. Bian, L. Li, Y. Liu, B. Zhao, Y. Chen, R. Wu, A. Li, L. Yao, P. Chen, Y. Zhang, X. Tian, F. Beermann, M. Wu, J. Han, P. Huang, T. Lin, and Q. Wu, Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway. Nat Chem Biol, 2014. 10(2): 133-40.

(43) R. Wang, J. He, M. Su, J. Luo, M. Xu, X. Du, H. Chen, W. Wang, Y. Wang, N. Zhang, B. Zhao, W. Zhao, Z. Shan, J. Han, C. Chang, and Q. Wu, The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Mol Med, 2013. 5(1): 137-48.

(44) H. Chen, L. Li, W. Wang, X. Du, Q. Wen, J. He, B. Zhao, G. Li, W. Zhou, Y. Xia, Q. Yang, C. Hew, Y. Liou, and Q. Wu, Prolyl isomerase Pin1 stabilizes and activates orphan nuclear receptor TR3 to promote mitogenesis. Oncogene, 2012. 31(23): 2876-87.

(45) Y. Zhan, X. Du, H. Chen, J. Liu, B. Zhao, D. Huang, G. Li, Q. Xu, M. Zhang, B. Weimer, D. Chen, Z. Cheng, L. Zhang, Q. Li, S. Li, Z. Zheng, S. Song, Y. Huang, Z. Ye, W. Su, S. Lin, Y. Shen, and Q. Wu, Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol, 2008. 4(9): 548-56.

(46) H. Chen, B. Zhao, W. Zhao, L. Li, B. Zhang, and Q. Wu, Akt phosphorylates the TR3 orphan receptor and blocks its targeting to the mitochondria. Carcinogenesis, 2008. 29(11): p. 2078-88.

(47) W. Zhao, M. Tian, B. Zhao, G. Li, B. Liu, Y. Zhan, H. Chen, and Q. Wu, Orphan receptor TR3 attenuates the p300-induced acetylation of retinoid X receptor-alpha. Mol Endocrinol, 2007. 21(12): 2877-89.

授權(quán)發(fā)明專利：

（1）發(fā)明人：劉小龍，趙必星，劉景豐，譚雄紅. 一種光調(diào)控T細(xì)胞活化的表達(dá)載體、構(gòu)建方法及應(yīng)用. 授權(quán)號(hào)：201610404536.9, 授權(quán)日期：20200110, 專利權(quán)人: 福州市傳染病醫(yī)院

獲獎(jiǎng)情況

福建省科技進(jìn)步一等獎(jiǎng)，《肝癌微創(chuàng)與診療一體化技術(shù)的研究及應(yīng)用》，排名第9，2022

福建省抗癌協(xié)會(huì)科技進(jìn)步獎(jiǎng)一等獎(jiǎng)，《肝細(xì)胞癌復(fù)發(fā)轉(zhuǎn)移分子標(biāo)志物篩選及機(jī)制研究》，排名第1，2022

福州市最美科技工作者，2022

百千萬人才工程省級(jí)人選，2021

福建省第二批“雛鷹計(jì)劃”青年拔尖人才，2021

第四屆福州青年科技獎(jiǎng)，2020

福建省自然科學(xué)獎(jiǎng)一等獎(jiǎng)，《孤兒受體TR3通過信號(hào)轉(zhuǎn)導(dǎo)通路抑制腫瘤細(xì)胞生長的新機(jī)制》，排名第4，2013

廈門市科技進(jìn)步一等獎(jiǎng)，《原發(fā)性肝癌的基礎(chǔ)與臨床應(yīng)用研究》，排名第8，2012